Various lysates were subjected to SDS PAGE followed by western blot with 13395-1-AP (CD86 antibody) at dilution of 1:2000 incubated at room temperature for 1.5 hours.

Immunofluorescent analysis of (4% PFA) fixed raji cells using CD86 antibody (13395-1-AP) at dilution of 1:200 and CoraLite®488-Conjugated AffiniPure Goat Anti-Rabbit IgG(H+L).

1X10^6 Raji cells were stained with 0.2ug CD86 antibody (13395-1-AP, red) and control antibody (blue). Fixed with 90% MeOH blocked with 3% BSA (30 min). Alexa Fluor 488-conjugated AffiniPure Goat Anti-Rabbit IgG(H+L) with dilution 1:1000.

1X10^6 untreated or LPS-treated mouse splenocytes were surface stained with 0.125 ug FITC Plus Anti-Mouse CD86 (FITC-65068, Clone: GL1). Cells were not fixed.

1X10^6 LPS treated mouse splenocytes were surface stained with 0.125 ug FITC Plus Anti-Mouse CD86 (FITC-65068, Clone: GL1) (red) or 0.125 ug FITC-rat IgG2a isotype control. Cells were not fixed.

1X10^6 untreated or LPS-treated mouse splenocytes were surface stained with 0.2 ug PE Anti-Mouse CD86 (PE-65068, Clone: GL1). Cells were not fixed.

1X10^6 untreated (dashed line) or LPS-treated mouse splenocytes were surface stained with 0.2 ug PE Anti-Mouse CD86 (PE-65068, Clone: GL1) (red), or 0.2 ug Isotype Control (blue). Cells were not fixed.

1X10^6 untreated (dashed lines) or LPS-treated (red) mouse splenocytes were surface stained with 0.2 ug APC Anti-Mouse CD86 (APC-65068, Clone:GL1) (red), or 0.2 ug Isotype Control (blue). Cells were not fixed.

1X10^6 untreated or LPS-treated mouse splenocytes were surface stained with 0.2 ug APC Anti-Mouse CD86 (APC-65068, Clone:GL1). Cells were not fixed.

1X10^6 human PBMCs were surface co-stained with FITC Anti-Human CD14 and 5 ul APC Anti-Human CD86 (APC-65165, Clone:BU63) or unstained. Cells were not fixed. Monocytes were gated.

1X10^6 human PBMCs were surface stained with 5 ul APC Anti-Human CD86 (APC-65165, Clone:BU63) or unstained. Cells were not fixed. Monocytes were gated.

1x10^6 human PBMCs were treated with FC Receptor Block then surface stained with 0.1 ug Anti-Human CD86 Rabbit Recombinant Antibody (65514-1-RR, Clone:BU63) or Rabbit IgG control PolyAb (30000-0-AP), and CoraLite®647-conjugated AffiniPure F(ab')2 Fragment Donkey Anti-Rabbit IgG (H+L) (SA00014-7). Cells were not fixed. Monocytes were gated.

1x10^6 human PBMCs were treated with FC Receptor Block then surface stained with 0.1 ug Anti-Human CD86 Rabbit Recombinant Antibody (65514-1-RR, Clone:BU63) or Rabbit IgG control PolyAb (30000-0-AP), and CoraLite®647-conjugated AffiniPure F(ab')2 Fragment Donkey Anti-Rabbit IgG (H+L) (SA00014-7). Cells were not fixed. Monocytes were gated.

1X10^6 Daudi cells were surface stained with 0.20 ug Anti-Human CD86 (65165-1-Ig, Clone: BU63) (red) or 0.20 ug isotype control antibody (blue) and CoraLite®488-Conjugated AffiniPure Goat Anti-Mouse IgG(H+L) with dilution of 1:1000. Cells were not fixed.

Immunofluorescent analysis of (4% PFA) fixed Raji cells using CD86 antibody (65165-1-Ig, Clone: BU63 ) at dilution of 1:1000 and CoraLite®488-Conjugated AffiniPure Goat Anti-Mouse IgG(H+L).

1x10^6 human PBMCs were treated with FC Receptor Block then surface stained with 0.1 ug Anti-Human CD86 Rabbit Recombinant Antibody (65514-1-RR, Clone:BU63) or Rabbit IgG control PolyAb (30000-0-AP), and CoraLite®647-conjugated AffiniPure F(ab')2 Fragment Donkey Anti-Rabbit IgG (H+L) (SA00014-7). Cells were not fixed. Monocytes were gated.

1x10^6 human PBMCs were treated with FC Receptor Block then surface stained with 0.1 ug Anti-Human CD86 Rabbit Recombinant Antibody (65514-1-RR, Clone:BU63) or Rabbit IgG control PolyAb (30000-0-AP), and CoraLite®647-conjugated AffiniPure F(ab')2 Fragment Donkey Anti-Rabbit IgG (H+L) (SA00014-7). Cells were not fixed. Monocytes were gated.